223 related articles for article (PubMed ID: 22639163)
21. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA
Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
23. Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.
Ryu JI; Han MH; Cheong JH; Kim JM; Kim CH
Immunotherapy; 2017 Mar; 9(5):411-421. PubMed ID: 28357913
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy of CNS malignancies.
Plautz GE; Shu S
Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo expansion of hematopoietic cells and their clinical use.
Aglietta M; Bertolini F; Carlo-Stella C; De Vincentiis A; Lanata L; Lemoli RM; Olivieri A; Siena S; Zanon P; Tura S
Haematologica; 1998 Sep; 83(9):824-48. PubMed ID: 9825579
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.
Ogbomo H; Cinatl J; Mody CH; Forsyth PA
Trends Mol Med; 2011 Aug; 17(8):433-41. PubMed ID: 21507717
[TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
30. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
31. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
32. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy for malignant glioma.
Mitchell DA; Fecci PE; Sampson JH
Cancer J; 2003; 9(3):157-66. PubMed ID: 12952301
[TBL] [Abstract][Full Text] [Related]
34. T-cell-associated cellular immunotherapy for lung cancer.
Li K; Zhang Q; Zhang Y; Yang J; Zheng J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1249-58. PubMed ID: 25381064
[TBL] [Abstract][Full Text] [Related]
35. Cell-Based Immunotherapy of Gliomas.
Everson RG; Antonios JP; Liau LM
Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
[TBL] [Abstract][Full Text] [Related]
36. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.
Grimm EA; Jacobs SK; Lanza LA; Melin G; Roth JA; Wilson DJ
Symp Fundam Cancer Res; 1986; 38():209-19. PubMed ID: 3489259
[TBL] [Abstract][Full Text] [Related]
38. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
Moriki A
Nihon Geka Hokan; 1989 Jan; 58(1):107-18. PubMed ID: 2802908
[TBL] [Abstract][Full Text] [Related]
39. [Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis].
Miyatake S; Kondou S; Aoki T; Iwasaki K; Ohyama K; Ootsuka S; Oda Y; Kikuchi H
No Shinkei Geka; 1991 Nov; 19(11):1053-9. PubMed ID: 1762655
[TBL] [Abstract][Full Text] [Related]
40. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
